# Ascletis Pharma

Source: https://onco.cc/companies/ascletis/  
OnCo record `ascletis` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ascletis is a Hangzhou biotech listed in Hong Kong, first known for hepatitis C antivirals, which sponsors phase 3 cancer trials among its liver-disease and metabolic programmes.

## Summary

Ascletis Pharma, headquartered in Hangzhou and listed in Hong Kong, began with direct-acting antivirals for hepatitis C in China and has since moved into liver disease, metabolic disease and oncology, including a PD-L1 antibody programme. ClinicalTrials.gov lists Ascletis as lead sponsor of a phase 3 cancer trial.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ascletis Pharmaceuticals Co., Ltd.; Ascletis Pharma Inc.; 歌礼制药
- Tags: ctgov-sponsor
- HQ: Hangzhou
- Type: biotech
- Website: https://www.ascletis.com

## Sources

- Official website: https://www.ascletis.com
- ClinicalTrials.gov: trials led by Ascletis Pharmaceuticals Co., Ltd.: https://clinicaltrials.gov/search?lead=Ascletis%20Pharmaceuticals%20Co.%2C%20Ltd.
- Wikidata: https://www.wikidata.org/wiki/Q140045748

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/ascletis.json